ValuEngine Downgrades Bellus Health (BLUSF) to Sell
Bellus Health (OTCMKTS:BLUSF) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.
Bellus Health (OTCMKTS BLUSF) traded down $0.01 during trading on Friday, reaching $0.32. 14,000 shares of the company traded hands, compared to its average volume of 16,353. Bellus Health has a 12-month low of $0.18 and a 12-month high of $0.36.
Bellus Health Company Profile
BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company’s pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough.
Receive News & Stock Ratings for Bellus Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health Inc. and related stocks with our FREE daily email newsletter.